Chair & CEO at Eli Lilly and Company
AI can find targets, propose molecules, and flag some toxicity earlier. It makes the front end faster. But you still have to test drugs in real people across many countries over long periods. Most cost and time sits in rigorous clinical trials, so AI improves odds but does not erase the need for careful testing.
This answer is part of a full interview with Dave Ricks, Chair & CEO at Eli Lilly and Company.
Found this insight valuable? Share it with your network to help others learn from Dave Ricks's experience.
Use this answer in your research, article, or academic work